sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment
Ying Huang(Nanjing Drum Tower Hospital), Baorui Liu(Nanjing University of Chinese Medicine)
Cited by 21
Related Papers
iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer
|Nature Communications|2019|126
Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy
|Nature Communications|2022|102
Gambogic acid-loaded biomimetic nanoparticles in colorectal cancer treatment
|International Journal of Nanomedicine|2017|78
H5N1 influenza virus-specific miRNA-like small RNA increases cytokine production and mouse mortality via targeting poly(rC)-binding protein 2
|Cell Research|2018|77
Radiomic analysis using contrast-enhanced CT: predict treatment response to pulsed low dose rate radiotherapy in gastric carcinoma with abdominal cavity metastasis
|Quantitative Imaging in Medicine and Surgery|2018|52